These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32176823)

  • 1. Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells.
    Kanasugi J; Hanamura I; Ota A; Karnan S; Lam VQ; Mizuno S; Wahiduzzaman M; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Takami A
    Cancer Sci; 2020 May; 111(5):1663-1675. PubMed ID: 32176823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer.
    Ma L; He H; Jiang K; Jiang P; He H; Feng S; Chen K; Shao J; Deng G
    Aging (Albany NY); 2020 Apr; 12(7):6352-6369. PubMed ID: 32283544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
    Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
    Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of
    Zhu YX; Shi CX; Bruins LA; Jedlowski P; Wang X; Kortüm KM; Luo M; Ahmann JM; Braggio E; Stewart AK
    Cancer Res; 2017 Aug; 77(16):4317-4327. PubMed ID: 28619709
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
    Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
    Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
    Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.
    Ge NL; Rudikoff S
    Oncogene; 2000 Aug; 19(36):4091-5. PubMed ID: 10962569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.
    Kim C; Lee JH; Ko JH; Chinnathambi A; Alharbi SA; Shair OHM; Sethi G; Ahn KS
    Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31284669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
    Manni S; Carrino M; Manzoni M; Gianesin K; Nunes SC; Costacurta M; Tubi LQ; Macaccaro P; Taiana E; Cabrelle A; Barilà G; Martines A; Zambello R; Bonaldi L; Trentin L; Neri A; Semenzato G; Piazza F
    Oncotarget; 2017 Feb; 8(9):14604-14619. PubMed ID: 28099937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
    Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
    Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.
    Herrero AB; Quwaider D; Corchete LA; Mateos MV; García-Sanz R; Gutiérrez NC
    J Cell Mol Med; 2020 Apr; 24(7):4171-4182. PubMed ID: 32141701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy.
    Manfrini N; Mancino M; Miluzio A; Oliveto S; Balestra M; Calamita P; Alfieri R; Rossi RL; Sassoè-Pognetto M; Salio C; Cuomo A; Bonaldi T; Manfredi M; Marengo E; Ranzato E; Martinotti S; Cittaro D; Tonon G; Biffo S
    Cancer Res; 2020 Nov; 80(21):4693-4706. PubMed ID: 32963011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines.
    Hausmann S; Brandt E; Köchel C; Einsele H; Bargou RC; Seggewiss-Bernhardt R; Stühmer T
    PLoS One; 2015; 10(4):e0122689. PubMed ID: 25837824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.
    Amachi R; Hiasa M; Teramachi J; Harada T; Oda A; Nakamura S; Hanson D; Watanabe K; Fujii S; Miki H; Kagawa K; Iwasa M; Endo I; Kondo T; Yoshida S; Aihara KI; Kurahashi K; Kuroda Y; Horikawa H; Tanaka E; Matsumoto T; Abe M
    Oncotarget; 2016 Oct; 7(43):70447-70461. PubMed ID: 27626482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
    Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.